Taken together, our data suggest that despite the importance of ABCB1 in multidrug resistance, its expression cannot be utilized as a biomarker to identify those prostate cancer patients that may be resistant to DTX prior to chemotherapy. Here, ABCB1 is linked to prostate carcinoma.